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ABSTRACT 
Objective: The objective of the present investigation was to develop a novel, simple and economic method for the determination of metformin 
(MET), linagliptin (LIN) and saxagliptin (SAX) in jentadueto and kombiglyze sample by employing the liquid chromatography and mass 
spectrometric method for estimation in bulk and pharmaceutical dosage form in presence of degradation products.  
Methods: The chromatographic separation was achieved by using the mobile phase composition of methanol and ammonium acetate buffer pH 4.5 
(85:15 % v/v) on the Hypurity advance C-18 column at a flow rate of 0.5 ml/min. Ion signals m/z “130.10/70.10, 473.10/420.40 and 
316.30/180.20” for metformin, linagliptin and saxagliptin respectively measured in positive ion mode. The detailed validation of the method was 
performed as per ICH guidelines.  
Results: The results of all validation parameters found within acceptance limits. The linearity of the drugs was found to be in the concentration 
range of 50–5000 ng/ml for all the drugs. Accuracy of the drugs was found to be from 94-102% and precision was found 4.67% RSD for all three 
drugs. The validated method was employed for the determination of drugs in the formulation and also determined the drugs in the presence of 
degradation products under stress conditions. 
Conclusion: The method was developed and validated as per guidelines. Hence, this method can be used for the simultaneous determination of 
metformin, linagliptin and metformin, saxagliptin in bulk and combined dosage forms. 
Keywords: Linagliptin, LC-MS, Method development, Metformin, Saxagliptin, Validation 




Biguanide class drug metformin hydrochloride (N,N-dimethyl imido 
carbonamide diamide), an oral anti-diabetic drug is used as a first-
line choice for the treatment of type 2 diabetes, particularly in 
overweight or obese people and those with normal kidney function. 
Metformin reduces hyperglycemia, primarily through its 
suppressive action on hepatic gluconeogenesis and also by 




dione] is a novel dipeptidyl peptidase-4 inhibitor representing a new 
therapeutic approach by stimulating glucose-dependent insulin 
release and reduction of glucagon levels. It acts through inhibiting 
the inactivation of incretins particularly glucagon-like peptide-1 and 
gastric inhibitory polypeptide [4, 5].  
Saxagliptin is a potent, selective, reversible dipeptidyl peptidase 4 
(DPP4) inhibitor specifically designed for extended inhibition of the 
DPP4 enzyme. Saxagliptin is recently approved for treatment of 
type-II diabetes mellitus [6]. DPP-4 inhibitors represent a new 
therapeutic approach to the treatment of type-II diabetes that 
functions to stimulate glucose-dependent insulin release and reduce 
glucagon levels. This is done through inhibition of incretins 
inactivation, particularly glucagon-like peptide-1 and gastric 
inhibitory polypeptide, thereby improving glycemic control [7]. 
A few analytical methods were reported for the determination of 
MET, LIN and SAX in individual/combined dosage forms [8-23]. The 
present investigation was to develop a novel, simple and economic 
method for the determination of MET, LIN and SAX in jentadueto 
and Kombiglyze sample by employing the liquid chromatography 
and mass spectrometric method for estimation in bulk and 
pharmaceutical dosage form. Further, it is applied for studying of 
stress degradation of the drugs. 
MATERIALS AND METHODS 
Instrumentation 
The instruments employed in the present study are as follows; HPLC-
Agilent 1200 Series, AB Sciex API-3200 with Analyst Software 1.4.2, 
Agilent technologies, Santa Clara, USA, centrifuge apparatus-Multifuge, 
Thermofisher scientific, Mumbai, India, sonicator-Sharp Analytical, 
Hyderabad, India, rotary shaker-Vibramax, Germany, analytical 
balance-Metler Toledo, Mumbai, India, Pipettes-Thermo Electron, UK.  
Chemicals 
Metformin hydrochloride (MET, 99.35%), linagliptin (LIN, 98.26%) 
and saxagliptin (SAX, 99.59%) are from Clearsynth Company, 
Mumbai, India. ammonium acetate, formic acid and methanol are 
purchased from Merck Ltd, Mumbai, India.  
Stock and working solution preparation 
Preparation of MET standard stock solution: 6.240 mg of MET has 
weighed accurately and transferred to 5 ml volumetric flask, then 
added methanol to dissolve and made up to mark with methanol to 
get the 1 mg/ml solution of MET.  
Preparation of LIN standard stock solution: 5.124 mg of LIN was 
weighed accurately and transferred to 5 ml volumetric flask, then 
added methanol to dissolve and made up to mark with methanol. 
The resultant solution was 1 mg/ml. a solution of LIN. 
Preparation of SAX standard stock solution: 5.214 mg of SAX was 
weighed accurately and transferred to 5 ml volumetric flask, then 
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added methanol to dissolve and made up to mark with methanol. 
The resultant solution was 1 mg/ml solution of SAX. 
Preparation of Mobile phase: Weighed and transferred 0.7708 g of 
ammonium acetate dissolved it in 1000 ml of water and adjusted the 
pH of the solution to 4.5 with formic acid. 150 ml of above solution 
was diluted with 850 ml of methanol, mixed and sonicated. This 
mixture was used as mobile phase. 
Sample preparations 
Sample preparation for metformin in jentadueto: Ten tablets were 
weighed and the coats were removed by carefully rubbing with a 
clean tissue wetted with methanol, 5 ml of methanol was added to 
an accurately weighed amount of the finely powdered jentadueto 
tablets equivalent to 500 mg of metformin and 2.5 mg of linagliptin, 
sonicated for 25 min and then made up to 10 ml with methanol. The 
resulting solutions were found to be 250 µg/ml of linagliptin and 
50,000µg/ml of metformin. 
To 0.050 ml of sample, 950.00 ml of the mobile phase was added and 
vortexed. Then the sample was transferred to autosampler vial, 
loaded the vials into autosampler and injected 10 µl of sample into 
LC/MS/MS system. The same procedure was followed for the 
preparation of metformin samples of Kombiglyze sample.  
Sample preparation for linagliptin in jentadueto: Ten tablets of jentadueto 
was weighed and then finely powdered. An accurately weighed portion 
of the powder equivalent to 2000 mg of metformin and 10 mg of 
linagliptin was transferred to 100 ml volumetric flask and 50 ml 
methanol was added and sonicated for 25 min. Then the volume was 
made up to 100 ml with methanol and was filtered. 0.05 ml of jentadueto 
sample was diluted with 150.0 ml of mobile phase and vortexed. Then 
the sample was transferred to autosampler vial, loaded the vials into 
autosampler and injected 10 µl of sample into LC/MS/MS system. 
Sample preparation for saxagliptin in kombiglyze: 0.050 ml of kombigylze 
sample was diluted with 150.0 ml of mobile phase and vortexed. Then 
the sample was transferred to autosampler vial, loaded the vials into 
autosampler and injected 10 µl of sample into LC/MS/MS system. 
Instrument parameters and characterization of production 
using mass spectrometry 
One micromole of MET, LIN and SAX solutions were separately 
infused into the mass spectrometer at a flow rate of 10 µl/min, to 
characterize the productions of each compound. The precursor ions 
[M+H]+ and the pattern of fragmentation were monitored using the 
positive ion mode. The major peaks observed in the MS/MS scan 
were used to quantify MET, LIN and SAX. The chromatographic 
conditions and multiple reaction monitoring (MRM) settings of the 
instrument were presented in [table 1]. 
 
Table 1: Chromatographic and mass conditions of the instrument (LC-MS) 
Chromatographic conditions MRM conditions** 
In source  Turbo ion spray  Curtain gas (CUR) 25.0 PSI 
Column Hypurity advance C-18 Collision gas (CAD) 5.0 PSI 
Mobile phase  Methanol: ammonium acetate buffer pH 4.5 (85:15 %v/v) Temperature (TEM) 550.0 °C 
Flow rate 0.5 ml/min Ion spray voltage 5500V 
Volume of injection 10 µl Gas-1 and Gas-2 40.0 PSI  
Run time 3 min Entrance potential 10.0 V 
Detection ions Collision cell exit potential MET-2.0 V 
LIN-5.0 V 
SAX-2.0 V 
Metformin  130.10* amu (parent) 70.10* amu (product) Declustering potential (DP)  MET-25.0 V 
LIN-55.0 V 
SAX-40.0 V 
Linagliptin 473.10* amu (parent) 420.40* amu (product) Collision energy MET-35.0 V 
LIN-33.0 V 
SAX-33.0 V 
Saxagliptin 316.30* amu (parent) 180.20* amu (product) 




The validation parameters like specificity, linearity, sensitivity, and 
accuracy, precision were done according to the ICH guidelines [24] 
and also referred few publications on method development and 
validation [25, 26]. Selectivity is studied by comparing the 
chromatograms obtained from placebo sample with the 
chromatogram obtained from tablets. Calibration standards are 
prepared by spiking required volume of working standard of MET, 
LIN and SAX solution in different 10 ml volumetric flasks and 
volume made up with methanol to yield concentration range of 50-
5000 ng/ml of drugs. The resultant peak areas of drugs were 
measured. The linearity of the method was determined by plotting 
the peak area (y) of drugs (MET, LIN and SAX) against normal 
concentration (x) of drugs, respectively. 
The lower limit of quantification (LLOQ) for drugs was defined as 
the lowest concentration giving a signal-to-noise ratio of at least 10-
fold, acceptable accuracy (80–120%), and precision (within 20%); 
this was verified by the analysis of 10 replicates. Intra-and inter-day 
accuracy and precision of this method were determined at three 
different concentration levels on three different days, and on each 
day, three replicates were analyzed. The accuracy and precision 
were expressed as percentage accuracy and relative standard 
deviation (R. SD, %) respectively, and calculated using following 





The drugs are in polar nature, so the reverse-phase chromatography 
was adopted using hydrophobic Hypurity advance, C-18 column (5µ, 
100 × 4.6 mm) at a 0.5 ml/min flow rate than evaluated various 
compositions of mobile phases to obtain better resolution and 
symmetric peak shapes of analyte as well as suitable retention time. 
Buffers like ammonium acetate, ammonium formate and acetic acid 
in various strengths were tried along with methanol as organic 
solvent. These buffers gave sharp peak shape, but poor response. 
Finally, the mobile phase consisting of 10 mmol ammonium acetate 
buffer: methanol (15:85) gave a sharp peak shape and good 
response. 
The mass spectrometric detection of drugs (MET, LIN and SAX) were 
investigated by ESI positive ion mode. In the positive ion mode, MET 
gave protonated molecular ions, [M+H]+, as the major species. The 
fragmentation patterns of the protonated molecular ions were 
evaluated by increasing the collision energy. The greatest intensities 
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were observed at 130.10/71.10 amu for MET, 473.40/420.40 amu for 
LIN and at 136.30/180.20 amu for SAX, respectively. The mass 
parameters were optimized by observing the maximal response of the 
productions. The transition of 130.10→71.10 amu, 473.40→ 420.40 
amu and 136.30 → 180.20 amu were used for detection of MET, LIN 
and SAX respectively. After optimization of the above conditions, the 
method was validated according to the ICH guidelines. The 
chromatograms of MET, LIN and SAX were shown in [fig. 1. a, 1. b, 1. c]. 
 
 
Fig. 1: Standard chromatogram of MET (1a), LIN (1b) and SAX (1c) 
 
Method validation 
Selectivity: The selectivity of the present method is established by 
checking the blank sample and observed the chromatogram. There is 
no interference found in retention times of MET, SAX and LIN in the 
blanks concludes the selectivity of the method. 
Linearity: The linearity of this method was evaluated by linear 
regression analysis, using the least square method. The drug 
concentrations were linear in a range of 50-5000 ng/ml. 
Calibration standards were prepared by spiking required volume 
of working standard (10000 ng/ml) solution along with internal 
standard into different 10 ml volumetric flasks and volume made 
up with methanol to yield concentrations 50, 100, 300, 1000, 2000 
and 5000 ng/ml of drugs. The resultant peak area of the drug was 
measured. A calibration curve was plotted between the peak area 
of the drug against the concentration of the drug.  
The [fig. 2] represents the linearity graph, regression coefficient 
(r2) including the slope and y-intercept. 
 
 
Fig. 2: Linearity graph of MET, LIN and SAX, n=6 
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Sensitivity: The lower limit of quantitation (LLOQ) was found to be 
50 ng/ml. The percent accuracy of LLOQ was 109.68%, and 
precision denoted by % RSD was 4.73%.  
Intra-day and Inter-day Precision and Accuracy: The intra-and inter-
day: precision and accuracy of this assay were determined by 
analyzing replicates of QC samples at three concentrations on three 
different days. The coefficients of variation for the intra-and inter-
day precisions were<4.67%. The intra-and inter-day accuracies 
were 94.50-102.50%. The low levels of coefficients of variation, i.e.: 
2.51%-4.67% [table 2] indicate the method is accurate and precise. 
All these criteria were acceptable and follow ICH. 
 
Table 2: Intra-day and inter-day accuracy and precision of MET, LIN and SAX 
 Standard MET LIN SAX 





mean±SD, % RSD  
Intra-day 
(n=6) 
150.35 142.09 94.5±2.38, 2.51 143.63 95.5±0.70, 0.73 142.1 94.5±2.38, 2.51 
1500 1501.55 102.42±3.64,3.56 1500.97 100.06±0.08, 0.08 1501.5 102.4±3.64, 3.56 
4000 4106.55 102.42±3.64,3.56 4000.93 100±0.03, 0.03 4106.49 102.4±3.64,3.56 
Inter-day 
(n=18) 
150.35 142.77 96.96±3.98, 4.10 143.96 95.53±1.26, 4.10 142.69 96.96±3.98, 4.10 
4009.15 1507.29 102.50±4.78,4.67 1501.87 99.82±0.48,0.48 1507.3 102.50±4.78,4.67 
4000 4109.29 102.50±4.78,4.67 4000.39 99.91±0.15,0.15 4109.4 102.50±4.78,4.66 
Note: Actual concentrations of drugs mentioned in ng/ml. Values are expressed in mean±SD 
 
Ruggedness: Ruggedness was studied along with precision and 
accuracy of batches where the effect of column change and analyst 
change were observed. The observed value for column variation and 
results obtained for precision and accuracy were within the 
acceptance criteria (i.e. there were no changes in the retention time, 
recovery and precision of the drug) according to US-FDA and ICH. 
Analysis of formulation of jentadueto and kombiglyze 
The samples were studied for various stress conditions like acid, 
base, hydrogen peroxide and photolytic conditions and the drug 
quantities were measured after standard and sample jentadueto and 
kombiglyze samples individually injected. Metformin standard 
solution and mixture of linagliptin and saxagliptin standard solution 
separately injected in six replicates.   
Along with the samples (jentadueto and kombiglyze) the standard 
solution samples were interspersed in a run and all the results are 
tabulated in [table 3] and [table 4]. The chromatograms of drugs, 
both the sample for jentadueto and kombiglyze were shown in [fig. 3 
(a) and 3 (b), and 4a and 4b] respectively. 
 
Table 3: Degradation data of drugs in jentadueto sample 
Sample MET (100ng/ml)* LIN (1000 ng/ml)* 
Standard 1199057±31741 1256839±65739 
0.1N HCl 3167698±96408 26158±1166 
1N HCl 2931780±100795 11637±1365 
0.1N NaOH 2324546±96459 25797±2432 
1N NaOH 1149570±39839 11944±754 
H2O2 3585314±168909 43640±1024 
Photolytic 3871644±149582 0.00±0.0 
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Fig. 3a: Chromatograms of MET in jentadueto sample and fig. 3. b. Chromatograms of LIN in jentadueto sample under stress conditions 
 
 
Fig. 4: Chromatograms of MET (4a) and SAX (4b) in kombiglyze sample under stress conditions 
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Table 4: Degradation data of drugs in kombiglyze sample 
Sample  MET (100ng/ml)*  SAX *(200 ng/ml)* 
 Standard 1199057±31741 1087995±23445 
0.1N HCl 2844320±80666 582.40±105 
1N HCl 1872539±106140 175.80±174 
0.1N NaOH 2200686±154669 0.00±0.00 
1N NaOH 1054260±29420 0.00±0.00 
H2O2 3589928±194918 45.80±102.41 
Photolytic 3430214±223323 905.60±73.21 
*Values expressed in mean±SD, n=3 
 
DISCUSSION 
The chromatographic method was optimized by changing various 
parameters, such as pH of the mobile phase, organic modifier and buffer 
used in the mobile phase. Under the presently prescribed conditions, the 
recoveries were found to be 94.5%-102.50% for MET, 95.5%-100.06% 
for LIN and 94.5%-102.5% for SAX. This indicates that commonly used 
excipients in jentadueto and kombiglyze samples were not interfering in 
the proposed method. Hence, this method is very useful for 
determination of MET, LIN and SAX in pharmaceutical dosage forms. It 
was also found that the differences of less than 5.0 % for three intra-and 
inter-day data reflect the precision of the method. The observation of % 
C. V less than 5.0 for both intra-and inter-day measurements also 
indicates a high degree of precision. In this study, the developed 
chromatographic method the linearity range of 50-5000ng/ml for three 
drugs will cover all the concentrations of drugs in a sample of jentadueto 
and kombiglyze. The LOQ of the method was 50ng/ml for all three drugs, 
it is a more sensitive method compared to reported method Asiya et 
al.2013 [28]. Owing to the high sensitivity the method was used to detect 
the drugs in different stress degradation conditions i.e. acidic, alkaline, 
and photolytic.  
The stress studies were conducted for LIN and MET combination by 
HPLC method. In acid and alkali hydrolysis of both MET and LIN 
were degraded by increasing the strength of acid and alkali and 
similarly degradation was also observed with peroxide. Further 
studies in photolytic degradation, MET was quantifiable significantly 
whereas LIN was found to be quantifiable but very low. LIN was 
completely degraded in the photolytic condition and detectability in 
either the drug or its degradants was not possible and hence no 
quantification of linagliptin by LCMS was observed. SAX was 
completely degraded in the alkaline and peroxide solutions but 
partially degraded in acidic and photolytic conditions. The 
saxagliptin (SAX) or its degradants were not detectable. Hence no 
quantification of saxagliptin was attempted. 
In the present study, Jentadueto was subjected to stress conditions 
like acid, base, peroxide, and photolytic degradation. This lead to 
there was no interference of degradants with the drug peaks. The 
degradation studies of jentadueto reveal that the developed method 
was stability indicating hence, this method can easily and 
conveniently adopted for routine quality control analysis of 
metformin and linagliptin in pure and its pharmaceutical dosage 
forms like jentadueto, This study was in agreement with Kavitha et 
al.,. 2013 (27) HPLC method.  
Further, in LC-MS analysis Stress-induced studies performed under 
different conditions employed like acid, base, peroxide, and 
photolytic. In each degradation study for both metformin and 
linagliptin it was observed that metformin was found to be stable in 
acidic media as compared alkaline media the degradation was more 
in alkali whereas, there are no changes in metformin content in 
peroxide and photolytic degradation. In case of linagliptin 
degradation was increased with acidity, similarly with alkali. In case 
of peroxide-induced degradation of linagliptin was found to be 
significant, but in case of photolytic degradation there was not a 
single fragment eluted in LC-MS method. 
Saxagliptin was completely degraded in the alkaline and peroxide 
solutions but partially degraded in acidic and photolytic conditions. 
The saxagliptin or its degradants were not detectable. Hence, no 
quantification of saxagliptin was attempted. It was found that the 
degradation of saxagliptin was found to be very highly significant 
(P<0.001) as mentioned from the [table 4]. 
Linagliptin was completely degraded in the photolytic condition and 
detectability in either the drug or its degradants was not possible and 
hence no quantification of linagliptin by LCMS was attempted. The stress 
studies were conducted for linagliptin and metformin combination by 
HPLC method. In acid and alkali hydrolysis of both metformin and 
linagliptin were degraded by increasing the strength of acid and alkali 
and similarly degradation was also observed with peroxide. Further 
studies in photolytic degradation, metformin were quantifiable 
significantly, whereas linagliptin was found to be quantifiable but very 
low. The degradation was highly significant (P<0.001) as mentioned in 
[table 3]. It may also be due to the concentration of linagliptin employed 
for the study was very low in case of the LCMS. 
CONCLUSION 
The present developed method indicates more sensitive than earlier 
methods reported in the literature. Jentadueto sample stress 
degradation studies indicate linagliptin was found to be sensitive 
against acidic, alkali, peroxide media but in photolytic studies totally 
degraded and not a single fragment detectable in LC-MS. In the case 
of kombiglyze sample, stress studies indicate saxagliptin was found 
to be highly sensitive against alkali media not a single fragment of 
saxagliptin was detectable. Further, saxagliptin was found to be 
quantifiable in other forced degradation studies like acidic, 
photolytic and peroxide. The method is highly useful for for 
quantification of metformin, linagliptin and saxagliptin in their 
combinations like Jentadueto and Kombiglyze. The method is novel 
and specific and can be applied as an alternative to HPLC as the 
analytical method is supported by forced degradation studies and 
the comparative data indicates the method is robust and specific 
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